• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Monaghan Medical touts Aerobika study

October 28, 2016 By Sarah Faulkner

Monaghan MedicalMonaghan Medical yesterday touted data from a 6-month retrospective study showing that its Aerobika device reduced drug use for treatment of chronic obstructive pulmonary device.

The Syracuse, N.Y.-based company says its oscillating positive expiratory pressure therapy device is designed to expand the airways, help expel mucus to the upper airways and aid in drug deposition.

The study included 810 COPD patients with chronic bronchitis. Half of the participants received treatment using the Aerobika device and the other half used propensity score-matched controls. Researchers hoped to evaluate if the Aerobika device could reduce moderate and severe exacerbations of COPD.

The study showed that for patients treated with Aerobika, antibiotics were used 57% less and oral corticosteroids were used 89% less than those treated without the device. Researchers also found that patients who used Aerobika exhibited lower costs throughout the study period, with an average reduction of $6,347 per patient at 30 days and almost $10,000 per patient at 6 months for all in-patient and out-patient costs.

They study demonstrated that using the device resulted in a 28% reduction in exacerbations in just 30 days of treatment, when used alongside usual COPD medications.

“One of our major goals in developing the Aerobika device was to safely improve patient outcomes,” VP clinical strategy & development Dominic Coppolo said in prepared remarks. “These real-world findings are encouraging as we continue to conduct additional studies to further demonstrate the impact of our device in this high risk patient population.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Respiratory Tagged With: Monaghan Medical Corporation

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS